Healthcare Disparities in Alopecia Areata
- Sponsor
- Momentum Data
- Study ID
- NCT05727306
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 95 Years
- Healthy Volunteers
- Not accepted
Interventions
- No intervention — OTHERObservational analysis of usual care only.
Study Details
Alopecia areata (AA) is a common immune-mediated non-scarring alopecia often associated with substantial morbidity. There are however, limited population-based data on potential disparities in the burden of AA, including across people of different ethnicities and deprivation. We aimed to provide the first large-scale, population-based estimate of lifetime risk of AA overall and by important sociodemographic subgroups. As AA is associated with an increased burden of mental health conditions and work-related outcomes (unemployment, time off work), a detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.
Key Dates
- Start date
- Oct 1, 2022
- Status verified
- May 2025
- Primary completion
- Jul 24, 2024
- Completion
- Aug 6, 2024
Study Design
- Enrollment
- 4,052,231 participants (actual)
Arms
- Arm: People with Alopecia AreataChildren and adults aged 12+ with new onset Alopecia Areata registered with a contributing General practitioner (GP) practice during the study period.
- Arm: People without Alopecia AreataChildren and adults aged 12+ without Alopecia Areata registered with a contributing GP practice during the study period.
Primary Outcome Measure
Likelihood of Depressive Episodes [ Time Frame: Data was collected retrospectively, assessed prior to and up to two years following initial Alopecia Areata diagnosis for each participant ]
Related Studies
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Regeneron AA Multicenter (Dupilumab)PHASE2 · Recruiting · Emma Guttman · Irvine, California
- CorEvitas Alopecia Areata (AA) Safety and Effectiveness RegistryRecruiting · CorEvitas · Waltham, Massachusetts
- Dupilumab in the Treatment of Pediatric Alopecia AreataPHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · Irvine, California